文献类型：期刊文献

英文题名：A case report of HER2-positive descending colon cancer with peritoneal metastasis and literature review

作者：Lv, Yaochun[1];Qian, Zhengpeng[2,3];Wu, Dewang[1];Zhu, Chengzhang[4];Zhang, Jipeng[2];Ning, Yeping[2];Du, Binbin[1,4]

第一作者：Lv, Yaochun

通信作者：Du, BB[1];Du, BB[2]

机构：[1]Gansu Clin Med Res Ctr Anorectal Dis, Lanzhou, Gansu, Peoples R China;[2]Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China;[3]Gansu Prov Hosp, Clin Med Res Ctr Anorectal Dis Gansu Prov, Lanzhou, Peoples R China;[4]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China

第一机构：Gansu Clin Med Res Ctr Anorectal Dis, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Gansu Clin Med Res Ctr Anorectal Dis, Lanzhou, Gansu, Peoples R China;[2]corresponding author), Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China.

年份：2025

卷号：15

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;Scopus(收录号：2-s2.0-105001420090);WOS:【SCI-EXPANDED(收录号:WOS:001454507100001)】；

基金：The author(s) declare that financial support was received for the research and/or publication of this article. This study was financially supported by the following projects: Gansu Province Health and Wellness Industry Scientific Research Project (Project No. GSWSHL2020-17); Lanzhou Municipal Science and Technology Program Project (Project No. 2022-ZD-47; 2022-5- 51; 2023-2-102).

语种：英文

外文关键词：HER2-positive descending colon cancer; peritoneal metastasis; anti-HER2 therapy; multidisciplinary collaboration (MDT); case report

摘要：Human epidermal growth factor receptor 2 (HER2) is an anti-cancer drug target for colon cancer. Among patients with colorectal malignancy (colorectal cancer, CRC), those with HER2 mutations have a poor overall prognosis and a significantly increased drug resistance. In recent years, anti-HER2 therapeutic drugs have developed rapidly. According to several clinical studies and case reports, anti-HER2 therapy, as an emerging anti-cancer approach, plays a crucial role in the treatment of HER2-positive CRC patients. Here, we present a case of HER2-positive descending colon cancer with peritoneal metastasis. The patient is a 26-year-old male, diagnosed with malignant tumor of the descending colon with peritoneal metastasis in April 2020. After multiple treatment modalities, the disease progressed. After chemotherapy with Trastuzumab Deruxtecan (T-DXd/DS-8201), the metastatic foci significantly shrank, and after surgical resection, a tumor-free state (NED) was achieved. Up to now, the patient's survival period has reached 56 months.